|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TBCK |
Gene summary for TBCK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TBCK | Gene ID | 93627 |
| Gene name | TBC1 domain containing kinase | |
| Gene Alias | HSPC302 | |
| Cytomap | 4q24 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024RDH3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 93627 | TBCK | CCI_1 | Human | Cervix | CC | 1.09e-04 | 6.22e-01 | 0.528 |
| 93627 | TBCK | CCI_3 | Human | Cervix | CC | 2.42e-08 | 7.82e-01 | 0.516 |
| 93627 | TBCK | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.39e-21 | -6.70e-01 | 0.0155 |
| 93627 | TBCK | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.78e-07 | -5.26e-01 | -0.1808 |
| 93627 | TBCK | HTA11_3361_2000001011 | Human | Colorectum | AD | 7.10e-05 | -5.57e-01 | -0.1207 |
| 93627 | TBCK | HTA11_696_2000001011 | Human | Colorectum | AD | 8.74e-06 | -3.46e-01 | -0.1464 |
| 93627 | TBCK | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.31e-03 | -6.82e-01 | -0.2061 |
| 93627 | TBCK | HTA11_866_3004761011 | Human | Colorectum | AD | 9.71e-09 | -4.53e-01 | 0.096 |
| 93627 | TBCK | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.99e-02 | -8.15e-01 | 0.0451 |
| 93627 | TBCK | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.12e-06 | -5.43e-01 | 0.0338 |
| 93627 | TBCK | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.28e-06 | -3.71e-01 | 0.0674 |
| 93627 | TBCK | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.30e-03 | -5.75e-01 | 0.2585 |
| 93627 | TBCK | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.03e-14 | -4.98e-01 | 0.3005 |
| 93627 | TBCK | A015-C-203 | Human | Colorectum | FAP | 5.76e-25 | -3.30e-01 | -0.1294 |
| 93627 | TBCK | A015-C-204 | Human | Colorectum | FAP | 3.31e-04 | -1.21e-01 | -0.0228 |
| 93627 | TBCK | A014-C-040 | Human | Colorectum | FAP | 6.98e-03 | -1.45e-01 | -0.1184 |
| 93627 | TBCK | A002-C-201 | Human | Colorectum | FAP | 1.48e-11 | -1.97e-01 | 0.0324 |
| 93627 | TBCK | A001-C-119 | Human | Colorectum | FAP | 1.81e-09 | -5.60e-01 | -0.1557 |
| 93627 | TBCK | A001-C-108 | Human | Colorectum | FAP | 7.82e-12 | -9.42e-02 | -0.0272 |
| 93627 | TBCK | A002-C-205 | Human | Colorectum | FAP | 4.31e-24 | -4.89e-01 | -0.1236 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:00435476 | Cervix | CC | positive regulation of GTPase activity | 53/2311 | 255/18723 | 8.72e-05 | 1.16e-03 | 53 |
| GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
| GO:0043547 | Colorectum | AD | positive regulation of GTPase activity | 75/3918 | 255/18723 | 7.95e-04 | 7.91e-03 | 75 |
| GO:00430871 | Colorectum | SER | regulation of GTPase activity | 77/2897 | 348/18723 | 5.90e-04 | 8.07e-03 | 77 |
| GO:00430872 | Colorectum | MSS | regulation of GTPase activity | 101/3467 | 348/18723 | 1.00e-06 | 3.46e-05 | 101 |
| GO:00435471 | Colorectum | MSS | positive regulation of GTPase activity | 68/3467 | 255/18723 | 7.97e-04 | 8.38e-03 | 68 |
| GO:0031929 | Colorectum | MSS | TOR signaling | 35/3467 | 126/18723 | 6.91e-03 | 4.44e-02 | 35 |
| GO:00430873 | Colorectum | FAP | regulation of GTPase activity | 85/2622 | 348/18723 | 1.20e-07 | 7.68e-06 | 85 |
| GO:00435472 | Colorectum | FAP | positive regulation of GTPase activity | 61/2622 | 255/18723 | 1.39e-05 | 3.73e-04 | 61 |
| GO:0090630 | Colorectum | FAP | activation of GTPase activity | 27/2622 | 115/18723 | 4.23e-03 | 2.90e-02 | 27 |
| GO:00430874 | Colorectum | CRC | regulation of GTPase activity | 69/2078 | 348/18723 | 1.11e-06 | 6.69e-05 | 69 |
| GO:00435473 | Colorectum | CRC | positive regulation of GTPase activity | 49/2078 | 255/18723 | 8.67e-05 | 1.77e-03 | 49 |
| GO:00430878 | Endometrium | AEH | regulation of GTPase activity | 66/2100 | 348/18723 | 1.26e-05 | 2.77e-04 | 66 |
| GO:00435477 | Endometrium | AEH | positive regulation of GTPase activity | 48/2100 | 255/18723 | 2.18e-04 | 2.67e-03 | 48 |
| GO:00906304 | Endometrium | AEH | activation of GTPase activity | 22/2100 | 115/18723 | 8.42e-03 | 4.60e-02 | 22 |
| GO:004308712 | Endometrium | EEC | regulation of GTPase activity | 67/2168 | 348/18723 | 1.84e-05 | 3.43e-04 | 67 |
| GO:004354712 | Endometrium | EEC | positive regulation of GTPase activity | 50/2168 | 255/18723 | 1.26e-04 | 1.66e-03 | 50 |
| GO:009063012 | Endometrium | EEC | activation of GTPase activity | 23/2168 | 115/18723 | 6.04e-03 | 3.57e-02 | 23 |
| GO:00319294 | Esophagus | ESCC | TOR signaling | 79/8552 | 126/18723 | 8.57e-05 | 6.21e-04 | 79 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TBCK | SNV | Missense_Mutation | rs866678116 | c.47N>T | p.Ala16Val | p.A16V | Q8TEA7 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
| TBCK | SNV | Missense_Mutation | c.2123C>T | p.Ala708Val | p.A708V | Q8TEA7 | protein_coding | tolerated(0.66) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TBCK | SNV | Missense_Mutation | rs762878213 | c.694N>C | p.Glu232Gln | p.E232Q | Q8TEA7 | protein_coding | tolerated(0.05) | possibly_damaging(0.733) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
| TBCK | SNV | Missense_Mutation | novel | c.2071N>A | p.Glu691Lys | p.E691K | Q8TEA7 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| TBCK | insertion | Nonsense_Mutation | novel | c.2078_2079insAATCAAATCA | p.Cys693Ter | p.C693* | Q8TEA7 | protein_coding | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| TBCK | SNV | Missense_Mutation | c.586N>C | p.Glu196Gln | p.E196Q | Q8TEA7 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| TBCK | SNV | Missense_Mutation | novel | c.1933G>A | p.Asp645Asn | p.D645N | Q8TEA7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| TBCK | SNV | Missense_Mutation | novel | c.953N>A | p.Ala318Glu | p.A318E | Q8TEA7 | protein_coding | tolerated(0.25) | benign(0.005) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TBCK | deletion | Frame_Shift_Del | rs746860249 | c.1370delN | p.Asn457ThrfsTer15 | p.N457Tfs*15 | Q8TEA7 | protein_coding | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| TBCK | deletion | Frame_Shift_Del | rs746860249 | c.1370delN | p.Asn457ThrfsTer15 | p.N457Tfs*15 | Q8TEA7 | protein_coding | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |